| 24-889 |
Hikma Pharmaceuticals USA Inc., et al. v. Amarin Pharma, Inc., et al. |
Federal Circuit |
2025-02-19 |
Granted |
CVSGAmici (4)Relisted (3) |
carve-out generic-drugs hatch-waxman-act induced-infringement patent-infringement skinny-label |
QP: When a generic drug label fully carves out a patented use, are allegations that the generic drugmaker calls its product a 'generic version' and ci… |
| 24-294 |
Norwich Pharmaceuticals Inc. v. Salix Pharmaceuticals, Ltd., et al. |
Federal Circuit |
2024-09-13 |
Denied |
|
fda-approval generic-drugs hatch-waxman-act injunctive-relief patent-law statutory-interpretation |
Whether 35 U.S.C. § 271(e)(4)(A) requires courts to issue overly broad injunctive orders that delay FDA approval of generic drug applications beyond t… |
| 23-1320 |
GlaxoSmithKline, LLC, et al. v. Superior Court of California, Alameda County |
California |
2024-06-18 |
Denied |
Amici (1) |
can the consumer's home state assert specific per brand-name-manufacturer due-process generic-drug generic-drugs innovator-liability personal-jurisdiction preemption product-liability specific-jurisdiction warning-label-liability |
When a plaintiff alleges injury from the consumption of a generic drug |
| 23A836 |
GlaxoSmithKline, LLC, et al. v. Superior Court of California, Alameda County |
California |
2024-03-12 |
Presumed Complete |
|
due-process generic-drugs personal-jurisdiction pharmaceutical-litigation specific-jurisdiction warning-label-liability |
Whether a brand-name pharmaceutical company can be subject to specific personal jurisdiction in a state for warning-label liability claims involving g… |
| 23-395 |
Alliance for Hippocratic Medicine, et al. v. Food and Drug Administration, et al. |
Fifth Circuit |
2023-10-16 |
Denied |
Amici (3) |
abortion abortion-medication administrative-procedure-act drug-regulation fda fda-approval generic-drugs medical-safety mifepristone subpart-h |
Whether Cross-Petitioners' challenge to FDA's 2000 mifepristone approval is timely |
| 22-37 |
Teva Pharmaceuticals USA, Inc. v. GlaxoSmithKline LLC, et al. |
Federal Circuit |
2022-07-13 |
Denied |
CVSGAmici (5)Relisted (3) |
active-inducement fda-approval generic-drug generic-drugs hatch-waxman-act inducement-doctrine patent-infringement skinny-label |
Whether a generic drug manufacturer can be held liable for inducing infringement of a patent on a use that its FDA-approved label has expressly carved… |
| 18-817 |
Hikma Pharmaceuticals USA Inc., et al. v. Vanda Pharmaceuticals Inc. |
Federal Circuit |
2018-12-27 |
Denied |
CVSGAmici (3)Relisted (2) |
generic-drugs inventive-concept medical-patent medical-treatment method-of-treatment natural-law patent-eligibility routine-and-conventional section-101 |
Whether patents that claim a method of medically treating a patient automatically satisfy Section 101 of the Patent Act, even if they apply a natural … |
| 18-546 |
Brian E. Frosh, Attorney General of Maryland, et al. v. Association for Accessible Medicines |
Fourth Circuit |
2018-10-25 |
Denied |
Amici (3)Response RequestedResponse WaivedRelisted (2) |
commerce-clause consumer-protection dormant-commerce-clause drug-pricing extraterritoriality federalism generic-drugs prescription-drugs price-control price-gouging state-police-powers state-regulation |
Does the Commerce Clause prohibit a state from protecting consumer access to essential off-patent and generic prescription drugs by requiring manufact… |
| 18-182 |
AIDS Healthcare Foundation, Inc. v. Gilead Sciences, Inc., et al. |
Federal Circuit |
2018-08-09 |
Denied |
Response Waived |
actual-controversy article-iii declaratory-judgment drug-exclusivity fda-approval generic-drugs patent-invalidity pharmaceutical pharmaceutical-patents standing |
Whether the 'actual controversy' requirement of the Declaratory Judgment Act requires a party seeking to introduce a generic drug product to file an a… |